Masato Okada

Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty‐Two–Week Randomized, Double‐Blind, Placebo‐Controlled Study

William Stohl, Andreas Schwarting, Masato Okada et al. · Arthritis & Rheumatology · 2017 · 391 citations · Full text

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

Peter Nash, Bruce Kirkham, Masato Okada et al. · The Lancet · 2017 · 390 citations · Full text

Rheumatoid Disorder, Rheumatology, Spirit-p2 Phase 3 +12

Dynamic landscape of immune cell-specific gene regulation in immune-mediated diseases

Mineto Ota, Yasuo Nagafuchi, Hiroaki Hatano et al. · Cell · 2021 · 327 citations

Inflammation, Immunogenetics, Autoimmune Disease +15

Cutting Edge: Fyn Is Essential for Tyrosine Phosphorylation of Csk-Binding Protein/Phosphoprotein Associated with Glycolipid-Enriched Microdomains in Lipid Rafts in Resting T Cells

Koubun Yasuda, Masakazu Nagafuku, Takaki Shima et al. · The Journal of Immunology · 2002 · 124 citations · Full text

Prevalence and Clinical Characteristics of Psoriatic Arthritis in Japan

Yuri Ohara, Mitsumasa Kishimoto, Naoho Takizawa et al. · The Journal of Rheumatology · 2015 · 80 citations · Full text